Author

Dalal A. Abou El Ella

h-index 22 View on Semantic Scholar

We have 4 of 45 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Design, synthesis, structure-activity relationship and in-silico studies of novel pyrazolo[1,5-a]pyrimidine derivatives as selective COX-2 inhibitors with promising anti-inflammatory activity and safety profile.

Selective COX-2 inhibitors offer effective anti-inflammatory therapy with minimized gastrointestinal side effects, yet developing novel scaffolds with superior safety profiles remains critical. In this study, a novel series of pyrazolo[1,5-a]pyrimidine derivatives (7a-b, 8a-j, 9a-b, and 12a-e) was designed using ligand...

Alaa Omar Mohamed Helmy, A. Taher, Eman Z. El Razaz et al. · Bioorganic chemistry (Print) · 0 citations

Open access Sep 2026

Dual inhibitors of CDK2 and TRKA kinases: design, synthesis, antiproliferative activity and molecular modeling of novel pyrazolopyrimidine derivatives

Simultaneous inhibition of CDK2 and TRKA presents a promising therapeutic avenue for cancer treatment, capitalizing on the critical roles of CDK2 in cell cycle regulation and TRKA in tumor cell survival and progression. In continuation of our previous work on dual CDK2/TRKA inhibitors, two series of pyrazolo[1,5-a]pyri...

Mohamed H. Attia, Deena S. Lasheen, Nermin Samir et al. · RSC Advances · 0 citations

Review Open access Jul 2026

FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches

This review analyzes how hinge contacts, back-pocket occupancy, and warhead placement govern activity across wild-type and mutant FLT3, and links binding mode, covalent engagement, and second-target selection to recurrent resistance biology to guide more resilient FLT3-targeted therapies for high-risk AML.

Fatma M Elmenier, Eman M. E. Dokla, Nermin Samir et al. · RSC Advances · 0 citations

#protein folding Open access Aug 2026

Design, synthesis, and nanomedicine based delivery of benzimidazole derivatives with promising antiproliferative activity.

These findings highlight benzimidazole derivatives, particularly 16a and 17b and their nanoparticle formulations, as promising anticancer candidates, driven primarily by strong cellular potency and favorable safety, substantiating their potential as lead candidates for further optimization and therapeutic development.

Mai Montaser Abdullah, Rania M. Hathout, Reham S. Elezaby et al. · RSC Medicinal Chemistry · 0 citations